The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia by Nygård, Lotta et al.
1The effect of non-steroidal anti-inflammatory drugs on 
benign prostatic hyperplasia 
Lotta H Nygård1, Kirsi Talala2, Kimmo Taari3, Teuvo LJ Tammela1,4, Anssi Auvinen5, Teemu J 
Murtola1,4 
1 University of Tampere, School of Medicine, Tampere, Finland 
2 Finnish Cancer Registry, Helsinki, Finland 
3 Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland 
4 Tampere University Hospital, Department of Urology, Tampere, Finland 
5 University of Tampere, School of Health Sciences, Tampere, Finland 
Running head: NSAIDs and benign prostatic hyperplasia 
Keywords: Benign prostatic hyperplasia; Cohort; Non-steroidal anti-inflammatory drugs; Risk 
Correspondence: Teemu J Murtola, Tampere University Hospital, Department of Urology, M-
building, 3rd floor, room 313, Teiskontie 35, PL 2000, 33521 Tampere, Finland. Tel. +358 3 311 
65015. E-mail: teemu.murtola@uta.fi  
Published original title: The effect of non-steroidal anti-inflammatory 
drugs on risk of benign prostatic hyperplasia.
"This is the peer reviewed version of the following article: The effect of non-steroidal anti-inflammatory drugs on 
risk of benign prostatic hyperplasia. Nygård Lotta, Talala Kirsi, Taari Kimmo, Tammela Teuvo, Auvinen Anssi, 
Murtola Teemu. The Prostate. 2017, 77(9), pp. 1029-1035, which has been published in final form at http://
dx.doi.org/10.1002/pros.23359. This article may be used for non-commercial purposes in accordance with Wiley 
Terms and Conditions for Self-Archiving."
  
2
ABSTRACT 
 
Background: Inflammation may play a role in pathogenesis of benign prostatic hyperplasia (BPH). 
However, the role of non-steroidal anti-inflammatory drugs (NSAIDs) as BPH risk factor is unclear. 
The objective of this study was to examine risk of BPH by NSAID use in a population-based cohort. 
Methods: A total of 74,754 Finnish men without previous BPH at baseline in 1996 - 1999 were 
linked to national medication reimbursement database for information on physician-prescribed 
NSAID purchases during 1995 - 2009. Information on BPH procedures and diagnoses was 
obtained from national Care Register for and Health Care. Cox regression with adjustment for age 
and use of cholesterol-lowering, antidiabetic and antihypertensive medication and NSAID use as 
time-dependent variable was used to analyse the risk of BPH surgery, medication use and 
recorded diagnosis. 
Results: Of the subjects 57,707 men (77.2 %) used prescription NSAIDs. The risk of BPH was 
elevated among NSAID users compared to non-users: HR 2.04, 95 % CI 1.97-2.10 for BPH 
medication use, HR 1.59, 95 % CI 1.47 - 1.71 for recorded diagnosis and HR 1.61, 95 % CI 1.49 - 
1.74 for surgery. The risk increase correlated with duration of NSAID usage, less with annual 
dosage. Nevertheless, the risk increase was observed already at short-term and low-dosage use. 
Conclusions: NSAID use is associated with an increased risk of BPH. The association is affected 
by systematic differences by NSAID use as the risk increase was observed already at short-term 
use. Nevertheless, the association correlated with duration of use, suggesting that NSAID usage or 
the conditions indicating it may increase BPH risk.
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INTRODUCTION 
 
Benign prostatic hyperplasia (BPH) is one of the most frequent medical conditions in aging men 
and one of the most common chronic diseases among the male population. BPH is progressive, as 
it evolves from asymptomatic tissue alterations to clinical disease with lower urinary tract 
symptoms (LUTS). These symptoms have an important effect on the quality of life and can lead to 
acute urinary retention if untreated [1]. Hence improvement in the prevention and clinical treatment 
of this condition would be beneficial. 
Although the pathogenesis and etiology of BPH are not entirely understood, hormonal 
dysregulation seems to play an essential role as a shift in prostatic androgen metabolism occurs 
with aging. This causes abnormal accumulation of dihydrotestosterone, resulting in prostate 
enlargement [2]. Also local growth factors and complex inflammation appear to have an impact on 
BPH. BPH is often accompanied by metabolic syndrome, a condition characterized by systemic 
inflammation [2]. Thus, use of non-steroidal anti-inflammatory drugs (NSAIDs) may affect BPH by 
reducing inflammation. NSAIDs are prescribed for analgesia in various common conditions with 
pain and inflammation. Both BPH and NSAID usage are common in older men which highlights the 
importance of understanding their interrelationship. 
Evidence regarding the role of inflammation in BPH has been accumulating and inflammatory 
pathways seem to play significant role in different phases of BPH. This has been indicated by 
histological studies reporting intraprostatic inflammation in 43 - 98 % of BPH tissue samples [3, 4]. 
High C-reactive protein concentration has also been associated with an increased BPH risk [5]. T-
cell derived cytokines may contribute and enhance prostatic growth [6] as various interleukins 
increase the expression of cyclooxygenase 2 (COX-2), which is up-regulated on macrophages and 
epithelial cells in BPH [7]. Thus inhibition of inflammatory pathways by NSAIDs could decrease and 
inhibit the development of BPH. Such an effect has been reported in vitro [8]. 
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The amount of research on this subject is scarce and results somewhat conflicting. One of the few 
studies reported a weak positive association between regular NSAID use and prevalent BPH/LUTS 
[9], whereas another study found a strong inverse association between daily NSAID use and 
incident BPH/LUTS [10]. Additionally, a systematic review and meta-analysis of randomized 
controlled trials on the subject concluded that NSAIDs improve lower urinary symptoms and urine 
flow [11]. Results from the Prostate Cancer Prevention Trial and from the Prostate, Lung, 
Colorectal, and Ovarian cancer screening trial provide no clear evidence that use of NSAIDs would 
reduce the BPH risk [12, 13]. More research on this subject is clearly needed to resolve the 
controversy.  
The aim of this study is to evaluate possible connections between NSAID usage and the BPH risk 
in a large population-based cohort. 
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MATERIALS AND METHODS 
 
Study cohort and data sources 
 
Study population consisted of men in the Finnish Randomized Study of Screening for Prostate 
Cancer (FinRSPC) which is the largest component of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC). The Finnish Trial included 80,144 men born in 1929 - 
1944 (aged 55, 59, 63 and 67 years at entry) resident in Tampere and Helsinki areas in 1996 - 
1999. These men were randomized either to be invited to screening with PSA test at four-year 
intervals (screening arm) or to the control arm with no intervention, both groups followed via 
national health-care registries. In total, 32,000 men were randomized to the screening arm. Men 
over 71 years old were no longer invited for re-screening (men 67 years old at entry were screened 
twice, whereas those aged 55, 59 or 63 years three times). The follow-up continued until the end of 
2013. 
This study was limited to include men from the FinRSPC study population who didn’t have any 
BPH medication purchases (finasteride or alpha-blockers, data available from 1995 onwards) and 
hadn’t undergone BPH-related surgery before baseline, the year of FinRSPC randomization. A 
total of 74,754 men were included in our study cohort. The follow-up continued until the first BPH 
treatment, emigration, death or beginning of 2013, whichever occurred first. Three different 
definitions were used for BPH treatment: recorded BPH diagnosis in a hospital contact, use of BPH 
medication (finasteride, dutasteride, tamsulosin, alfuzosin) or surgical treatment (transurethral 
resection of the prostate (TURP), laser resection/enucleation or intracapsular prostatectomy, 
performed extra- or transvesically). 
Detailed individual information on use of NSAIDs and other drugs (statins, antidiabetic drugs and 
antihypertensive drugs) was obtained from the reimbursement database of the Social Insurance 
Institution of Finland (SII). NSAIDs were identified using ATC-codes (Supplementary table 1). All 
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purchases of physician-prescribed drugs approved by the SII (most prescription drugs in clinical 
use) are recorded in the database. The database includes information on date, dosage, package 
size and number of obtained packages for each reimbursed purchase. The database does not 
record over-the-counter purchases or drugs administered during hospital inpatient periods. 
Information on over-the-counter NSAID use was collected with surveys mailed with the screening 
invitations on the third screening round, with 93 % response rate [14]. 
Yearly purchases of each NSAID were added together for total yearly mg amount of usage. 
Differences between drugs were standardized by dividing the yearly mg amount with amount 
corresponding to a Defined Daily Dose as listed by WHO [15]. Each year with registered NSAID 
purchases was regarded as a year of usage regardless of the purchased amount. Average yearly 
amount of NSAID usage was calculated by dividing the cumulative amount of use with the 
cumulative number of years with registered purchases.  
The information on diagnoses and medical procedures recorded at outpatient visit and 
hospitalization episodes was obtained from the Care Register for and Health Care (HILMO) 
maintained by the National Institute for Health and Welfare (THL). The ICD-10 code N40 was used 
to identify BPH diagnoses. BPH procedures were identified using NCSP (Nordic Classification of 
Surgical Procedures) codes KED00, KED10, KED22, KED33, KED62, KED72, KED52 and KED76. 
Additionally, we identified common diagnoses for regular NSAID use arthrosis and rheumatoid 
arthritis based on ICD-10 codes M15-M19 and M05-M06, respectively. 
Both registries cover all hospitals (whether public or private) and the entire population of Finland. 
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Statistical methods 
 
Risk of BPH was compared by overall NSAID usage, previous or current usage and by length of 
usage as compared to non-users. For comparison, BPH risk was separately analyzed by aspirin 
and coxib usage.  
The analysis was performed using Cox regression to calculate hazard ratios (HRs) and their 95 % 
confidence intervals (95 % CIs) for the three separate BPH outcomes defined earlier. Analysis was 
adjusted for age and use of other medications (statins, antidiabetic drugs and antihypertensive 
drugs). 
NSAID usage was analyzed as a time-dependent variable, with usage status, as well as 
cumulative length of usage were updated for each year of follow-up based on yearly NSAID 
purchases.  We performed separate analysis for NSAID ever-users, and an analysis of current 
users (men still using NSAIDs on a given follow-up year) and previous users (usage on previous 
years, but not on the observation year). 
Users were stratified into quartiles according the total cumulative number of years with recorded 
NSAID purchases. To estimate the role of yearly amount of NSAID use, the users were stratified to 
those who used less than 100 DDDs/year and men who used 100 DDD/year or more. Like status 
on NSAID usage, these variables were updated separately for each year of follow-up according to 
medication purchases.  
Additionally, one-year and three-year lag time analyses were performed to evaluate NSAIDs’ long-
term effects on BPH risk. In this analysis NSAID exposure was lagged forward in the follow-up 
time, for example in a three-year lag time analysis exposure in 1996 would affect the outcome on 
1999.  
The analyses were carried out using IBM SPSS Statistics 23 statistical software (Chicago, IL, 
USA). 
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RESULTS 
 
Population characteristics 
 
Of the 74,754 participants, 77.2 % were NSAID users (Table 1). The median age at baseline was 
59 years in both NSAID users and non-users. The use of antidiabetic drugs, antihypertensive 
drugs and statins was more common among NSAID users. 
 
BPH risk by NSAID usage 
 
The risks for BPH-related hospital visits, starting BPH-medication and BPH surgery were elevated 
among NSAID users compared to non-users in multivariable-adjusted analyses both for over-the-
counter and prescription usage (Table 2). The largest risk increase was observed for usage of BPH 
drugs, but also the risk of BPH surgery was increased compared to non-users. For prescription 
use, the risk was highest among men on NSAIDs, whereas in men who discontinued NSAIDs 
usage the risk elevation was reduced, but remained elevated compared to the non-users. The 
association was amplified with increasing years of NSAID usage. No clear risk trends were 
observed by annual amount of NSAID doses; the risk for each BPH endpoint was elevated in both 
men who had used less than 100 DDDs/year (85 % of users) and men who had used 100 
DDDs/year or more (15 % of users). For BPH diagnosis and BPH surgery the risk elevations were 
slightly higher among those who used less than 100 DDDs/year. 
 
 
 
  
9
BPH risk by use of aspirin and coxibs 
 
Similar to NSAID usage, the use of coxibs was associated with a higher risk of each BPH endpoint 
(Table 3). The risk association was somewhat weaker for aspirin; only the risk of BPH medication 
use was elevated among ever-users of prescribed aspirin (HR, 1.19; 95 % CI, 1.13 - 1.26) and 
over-the-counter users (HR 1.11; 95 % CI 1.04 - 1.19). However, among current prescription users, 
also the risks of BPH-related hospital visits and BPH surgery were elevated. The results were also 
similar in an analysis where NSAIDs and coxibs were included together in the Cox regression 
model to take into account simultaneous use of multiple groups of NSAIDs. 
 
Lag time analyses 
 
The association between NSAIDs and BPH risk was weaker in both 1- and 3-year lag time 
analyses compared to the main analysis, but still remained statistically significant, consistent with a 
short-term effect (Table 4). 
 
Subgroup analyses 
 
Age, BMI or antidiabetic drug use did not modify the association between ever-use of NSAIDs and 
risk of BPH surgery (Figure 1). The risk was modified, however, by use of statins and 
antihypertensive drugs (p for interaction 0.045 and 0.001, respectively); the risk elevation was not 
as strong among men who had also used these drug groups. 
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Sensitivity analyses 
 
Rheumatoid arthritis and arthrosis, which are common indications for NSAID use, were both 
associated with increased risk of starting BPH medication (HR 1.46, 95 % CI 1.13 - 1.89 and HR 
1.76, 95 % CI 1.35 - 2.28). However, neither was associated with the risk of having recorded BPH 
diagnosis or surgery. 
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DISCUSSION 
 
In our population-based cohort of Finnish men, NSAID users had a higher risk of BPH-related 
hospital visits, starting BPH medication and undergoing BPH surgery compared to non-users. The 
association was correlated with years of NSAIDs usage, and weakened after discontinuation, yet 
remaining significantly elevated compared to non-users. This shows that at population level, the 
risk association is opposite than would have been expected based on in vitro findings. 
Aspirin did not have a similar association with BPH risk. The reason may lie in different indications 
for aspirin use. In Finland NSAIDs are prescribed for analgesia, whereas aspirin is prescribed in 
combination with dipyridamole mainly for secondary prevention of stroke and cerebral circulatory 
disorders. It should be noted that our register-based data on aspirin prescriptions is an 
underestimation of true prevalence of usage, as in Finland for cardiovascular disease prevention 
aspirin is typically purchased over-the-counter due to its cheaper price. This may have diluted the 
observed risk associations by aspirin use. Nevertheless, the risk associations were similar also in 
the subgroup of men with information on over-the-counter aspirin use. 
The results show that either use of NSAIDs in itself or the conditions indicating their use increases 
the BPH risk and the probability of BPH progression to a stage requiring surgical management. 
The observed risk association is probably affected by both; strengthening risk association along 
with years of NSAID usage suggests direct effect of NSAIDs. On the other hand, the elevated risk 
observed even at low-dose usage and after discontinuation of usage suggests NSAID users differ 
in their BPH risk as a group from non-users. Overweight, which is associated with metabolic 
syndrome, and musculoskeletal disorders caused by it may be more common among NSAID 
users. Nevertheless, common indications for regular NSAID use were associated only with 
increased risk of BPH medication use, but not with risk of having recorded BPH diagnosis or 
surgery. Thus our results may not be entirely explained by confounding by indication, although 
indications for NSAID usage vary considerably and are hard to evaluate comprehensively even 
with our national register data. 
  
12
Metabolic syndrome has been linked to systemic inflammation [16], which may also increase the 
BPH risk [5]. Concordantly, the risk association was modified by background use of cholesterol-
lowering and antidiabetic drugs, suggesting that these conditions may have a role in the risk 
association. 
Our result differs from secondary analyses of previously published randomized controlled trials, 
which reported no association with BPH risk.  Contrary to this study, randomized trials often use 
highly selected study populations, which may lead to poor generalizability. Our study population 
was a population-based cohort with minimal exclusions due to background variables apart from 
having BPH at baseline. This is probably why the results of this study differ from those of previous 
randomized trials. This study proves that NSAID use does not decrease the number of BPH 
diagnoses nor the harmful effects of the condition at the population level. 
The findings of this study differ from some previous epidemiological studies. A population-based 
cohort study of 2,447 men reported that daily use of NSAIDs was associated with improved urinary 
symptoms, increased urine flow rate, and decreased prostate volume and prostate-specific antigen 
levels, i.e. indications of decreased prostatic volume [10]. In contrast to our study, NSAID use in 
that study was ascertained by a structured interview at baseline and by a questionnaire during the 
follow-up, meaning that possible changes in NSAID use over time were not thoroughly examined. 
Additionally, definition for BPH was somewhat different. In addition to BPH treatment (surgery or 
BPH medications), acute urinary retention, moderate/severe urinary symptoms (as assessed by 
the AUASI), time to low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml and 
serum PSA level >1.4 ng/ml were examined as endpoints. 
In another cohort study of 4,964 men NSAIDs were not associated with the BPH risk [12]. The 
main difference between that and our study is the size of the study population. Also, the data on 
current NSAID use was collected by interviewing the participants at baseline and at each follow-up 
contact, and BPH was defined as either surgery, medical treatment or sustained, clinically 
significant BPH symptoms. Only the initiation of NSAID use was taken into consideration, therefore 
the continuation was assumed. Also the information on dose wasn’t captured. Another difference 
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between our study and these two previous studies is the source of information on NSAID 
exposure; information collected through surveys likely catches over-the-counter usage for mild and 
transient need, whereas our study mainly included prescription usage. Thus in our study NSAID 
users likely had a condition for which prescription use was needed, and as a result the NSAID 
users as a group could differ between our study and the previous studies. 
Similar to our study, another study with a large study population, 34,694 participants, reported a 
modest excess risk for BPH among NSAID users [9]. In that study, the information on BPH was 
obtained by questionnaires where history of BPH (enlarged prostate or BPH told by a physician) or 
surgical treatment (TURP) was asked. The same questionnaires included the information on 
NSAID use, defined as regular use of aspirin or ibuprofen in last year. 
Our study has several strengths. A principal strength is the extensive and detailed data on 
prescribed NSAID use, as well as several information sources on BPH diagnoses and treatments. 
These made it possible to assess BPH on multiple levels, from medical treatment to surgery. In 
addition, the large study population and the long follow-up time increase the validity of this study. 
The limited information on the over-the-counter use of NSAIDs is one the limitations. It’s more than 
likely that some men who didn’t have NSAID prescriptions nevertheless had over-the-counter 
usage, causing exposure misclassification diluting the observed risk differences. Furthermore, 
detailed information on indications for NSAID use was not available, along with the knowledge of 
whether prescribed drugs were actually taken. Our information on BPH came from national health 
care registers, and the BPH cases in our study population represent men whose condition was 
severe enough to warrant medication use, health care contact or surgical treatment. We could not 
evaluate milder or non-symptomatic forms of BPH. 
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CONCLUSIONS 
 
The use of NSAIDs does not lower the risk of BPH at population level. On the contrary, the risk is 
higher compared to NSAID non-users.   
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Table 1. Population characteristics. Study cohort of 74,754 men without benign prostatic hyperplasia at 
baseline from the Finnish Randomized Study of Screening for Prostate Cancer.  
 NSAID usage 
 Yes No 
n (%) of men 57,707 (77.2 %) 17,047 (22.8 %) 
median age at baseline (IQR) 59.00 (55.00 - 63.00) 59.00 (55.00 - 63.00) 
median BMI (IQR)* 26.47 (24.39 - 29.07) 25.62 (23.67 - 28.33) 
BPH end-points occurring during 
follow-up: 
  
Initiation of BPH medication use; n (%) 17,822 (30.9 %) 2,552 (15.0 %) 
Median (IQR) follow-up until BPH 
medication 
12.00 (10.00 - 13.00) 12.00 (11.00 - 13.00) 
Recorded BPH diagnosis; n (%) 3,034 (5.3 %) 523 (3.1 %) 
Median (IQR) follow-up until BPH 
diagnosis 
12.00 (11.00 - 13.00) 12.00 (11.00 - 14.00) 
BPH surgery; n (%) 2,959 (5.1 %) 490 (2.9 %) 
Median (IQR) follow-up until BPH 
surgery 
12.00 (11.00 - 13.00) 12.00 (11.00 - 14.00) 
Use of other medications:   
n (%) of antidiabetic drug users  12,325 (21.4 %) 2,700 (15.8 %) 
n (%) of antihypertensive drug users 40,484 (70.2 %) 9,449 (55.4 %) 
n (%) of statin users 25,927 (44.9 %) 5,045 (29.6 %) 
 
BPH = benign prostatic hyperplasia, NSAID = non-steroidal anti-inflammatory drugs 
* Available for 11,220 men 
Table 2. Risk of benign prostatic hyperplasia by NSAID usage. Study cohort of 74,754 men without benign prostatic hyperplasia at baseline from the Finnish 
Randomized Study of Screening for Prostate Cancer.  
 BPH medication use Recorded BPH diagnosis BPH surgery 
 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
Over-the-counter NSAID use      
None Ref Ref Ref Ref Ref Ref 
Any 
1.29 
(1.19 - 1.40) 
1.26 
(1.16 - 1.37) 
1.27 
(1.03 - 1.58) 
1.26 
(1.02 - 1.57) 
1.23 
(0.99 - 1.53) 
1.22 
(0.98 - 1.51) 
Prescription NSAID use      
None Ref Ref Ref Ref Ref Ref 
Any 
2.14 
(2.07 - 2.20) 
2.04 
(1.97 - 2.10) 
1.64 
(1.53 - 1.77) 
1.59 
(1.47 - 1.71) 
1.67 
(1.55 - 1.80) 
1.61 
(1.49 - 1.74) 
Active users 
2.99 
(2.89 - 3.10) 
2.83  
(2.73 - 2.93) 
2.25 
(2.07 - 2.45) 
2.17 
(1.20 - 2.37) 
2.34 
(2.15 - 2.55) 
2.25 
(2.07 - 2.46) 
Previous users 
1.62 
(1.56 - 1.67) 
1.56  
(1.50 - 1.62) 
1.28 
(1.18 - 1.39) 
1.25 
(1.15 - 1.36) 
1.28 
(1.18 - 1.40) 
1.25 
(1.14 - 1.36) 
Years of use       
1 year 
1.75 
(1.68 - 1.82) 
1.71 
(1.64 - 1.77) 
1.36 
(1.24 - 1.49) 
1.34 
(1.22 - 1.47) 
1.36 
(1.24 - 1.50) 
1.34 
(1.22 - 1.48) 
2-3 years 
2.15 
(2.07 - 2.24) 
2.07 
(1.99 - 2.15) 
1.64 
(1.50 - 1.80) 
1.60 
(1.46 - 1.76) 
1.68 
(1.53 - 1.85) 
1.64 
(1.49 - 1.80) 
4-5 years 
2.47 
(2.35 - 2.60) 
2.34 
(2.23 - 2.47) 
1.80 
(1.59 - 2.03) 
1.73 
(1.54 - 1.96) 
1.91 
(1.69 - 2.15) 
1.84 
(1.63 - 2.08) 
6 years or 
longer 
2.96 
(2.80 - 3.14) 
2.78 
(2.62 - 2.95) 
1.91 
(1.67 - 2.17) 
1.83 
(1.60 - 2.08) 
1.88 
(1.65 - 2.15) 
1.80 
(1.58 - 2.06) 
Average number of DDDs per year      
less than 
100 DDD/year 
2.14 
(2.07 - 2.20) 
2.03 
(1.97 - 2.10) 
1.67 
(1.55 - 1.81) 
1.62 
(1.50 - 1.75) 
1.70 
(1.57 - 1.84) 
1.64 
(1.52 - 1.78) 
100 DDD/year 
or more 
2.14 
(2.04 - 2.25) 
2.04 
(1.94 - 2.14) 
1.48 
(1.31 - 1.67) 
1.42 
(1.25 - 1.60) 
1.52 
(1.34 - 1.72) 
1.46 
(1.29 - 1.65) 
 
BPH = benign prostatic hyperplasia, DDD = Defined Daily Dose, NSAID = non-steroidal anti-inflammatory drugs 
* From Cox regression model with adjustment for baseline age and antidiabetic-, antihypertensive- and cholesterol-lowering drug 
Table 3. Risk of BPH by use of aspirin and coxibs. Study cohort of 74,754 men without benign prostatic hyperplasia at baseline from the Finnish Randomized 
Study of Screening for Prostate Cancer.  
 BPH medication use Recorded BPH diagnosis BPH surgery 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
ASA usage 
Over-the-counter use 
None Ref Ref Ref Ref Ref Ref 
Any 
1.15 
(1.08 - 1.24) 
1.11 
(1.04 - 1.19) 
1.08 
(0.90 - 1.29) 
1.06 
(0.88 - 1.27) 
1.08 
(0.89 - 1.29) 
1.06 
(0.88 - 1.27) 
Prescription use 
None Ref Ref Ref Ref Ref Ref 
Any 
1.37 
(1.30 - 1.45) 
1.19 
(1.13 - 1.26) 
1.13 
(0.99 - 1.29) 
1.04 
(0.91 - 1.18) 
1.12 
(0.98 - 1.28) 
1.03 
(0.90 - 1.17) 
Active 
users 
1.87 
(1.72 - 2.04) 
1.63 
(1.49 - 1.77) 
1.62 
(1.33 - 1.97) 
1.49 
(1.22 - 1.82) 
1.53 
(1.24 - 1.88) 
1.40 
(1.13 - 1.72) 
Previous 
users 
1.17 
(1.09 - 1.25) 
1.02 
(0.95 - 1.09) 
0.93 
(0.79 - 1.10) 
0.86 
(0.72 - 1.01) 
0.96 
(0.81 - 1.13) 
0.88 
(0.74 - 1.04) 
Coxibs usage 
None Ref      
Any 
1.85 
(1.78 - 1.92) 
1.76 
(1.70 - 1.83) 
1.45 
(1.33 - 1.59) 
1.41 
(1.29 - 1.54) 
1.45 
(1.32 - 1.59) 
1.41 
(1.28 - 1.54) 
Active 
users 
2.09 
(1.97 - 2.22) 
1.99 
(1.88 - 2.12) 
1.52 
(1.30 - 1.77) 
1.48 
(1.27 - 1.72) 
1.44 
(1.22 - 1.69) 
1.40 
(1.19 - 1.64) 
Previous 
users 
1.74 
(1.66 - 1.83) 
1.66 
(1.58 - 1.75) 
1.45 
(1.30 - 1.61) 
1.40 
(1.26 - 1.57) 
1.46 
(1.31 - 1.62) 
1.41 
(1.27 - 1.57) 
 
BPH = benign prostatic hyperplasia, NSAID = non-steroidal anti-inflammatory drugs 
* From Cox regression model with adjustment for baseline age and antidiabetic-, antihypertensive- and cholesterol-lowering drug 
Table 4. Risk of BPH by NSAID usage in lag-time analysis. Study cohort of 74,754 men without benign prostatic hyperplasia at baseline from the Finnish 
Randomized Study of Screening for Prostate Cancer.  
 
 BPH medication use Recorded BPH diagnosis BPH surgery 
NSAID usage 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
HR age-adjusted 
(95% CI) 
HR multivar.-adjusted 
(95% CI)* 
1-year lag 
time 
None Ref      
Any 
1.61 
(1.56 - 1.65) 
1.52 
(1.47 - 1.56) 
1.39 
(1.30 - 1.49) 
1.34 
(1.25 - 1.44) 
1.43 
(1.33 - 1.53) 
1.37 
(1.27 - 1.48) 
3-year lag 
time 
None Ref      
Any 
1.50 
(1.46 - 1.55) 
1.42 
(1.38 - 1.47) 
1.27 
(1.19 - 1.36) 
1.23 
(1.14 - 1.31) 
1.29 
(1.20 - 1.38) 
1.24 
(1.15 - 1.33) 
 
BPH = benign prostatic hyperplasia  
* From Cox regression model with adjustment for baseline age and antidiabetic-, antihypertensive- and cholesterol-lowering drug 
 
Figure 1. Risk of BPH surgery by NSAID usage in subgroup analyses. Study cohort of 74,754 men without 
benign prostatic hyperplasia at baseline from the Finnish Randomized Study of Screening for Prostate 
Cancer. 
 
a) All NSAIDs 
 
* P for interaction ч0.05 
 b) Aspirin 
 
 
 
 
 
